論文種別 | 原著(症例報告除く) |
言語種別 | 英語 |
査読の有無 | その他(不明) |
表題 | Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models |
掲載誌名 | 正式名:Journal of gastroenterology and hepatology 略 称:J Gastroenterol Hepatol ISSNコード:08159319/14401746 |
掲載区分 | 国外 |
巻・号・頁 | 40(4),pp.930-939 |
著者・共著者 | Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). |
発行年月 | 2025/04 |
DOI | 10.1111/jgh.16871 |
PMID | 39762722 |